A deep longitudinal analysis of next generation influenza vaccines in older adults
Description: PROJECT NARRATIVE The estimated effectiveness of the influenza vaccine in the U.S. for the 2018-2019 influenza season in older adults (≥65 years) was only 12-13%, demonstrating an urgent need to develop new approaches to improve influenza vaccine responsiveness in this high-risk population who constitute 90% of the 36,000+ annual U.S. influenza deaths. In this project, we will recruit and longitudinally follow a cohort of 60 older adults, who will receive 3 different influenza vaccines over 3 subsequent influenza seasons, including the most commonly used vaccine Fluzone® High-Dose and the first FDA-approved adjuvanted influenza vaccine, FLUAD®. By performing comprehensive profiling of their blood antibodies and immune cells over time, we will be able to associate specific age-related immune alterations with vaccine responder or non-responder status, thus allowing us to pinpoint biological pathways that can be targeted to enhance vaccine efficacy and that can also help us to progress towards developing a universal influenza vaccine.
Funding type: cooperative_agreement
Funder scheme: U01
Start date: 2022-01-01
End date: 2026-12-31
Investigator: ADOLFO GARCIA-SASTRE
Institution: JACKSON LABORATORY
Funded outputs count: 21
Funder award ID: U01AI165452
OpenAlex ID: G9000907106